Sensitivity of fecal immunochemical test and risk factors for interval colorectal cancer in a French population.


Journal

Clinics and research in hepatology and gastroenterology
ISSN: 2210-741X
Titre abrégé: Clin Res Hepatol Gastroenterol
Pays: France
ID NLM: 101553659

Informations de publication

Date de publication:
03 2023
Historique:
received: 08 12 2022
revised: 20 01 2023
accepted: 06 02 2023
pubmed: 11 2 2023
medline: 8 3 2023
entrez: 10 2 2023
Statut: ppublish

Résumé

Colorectal cancer (CRC) screening using fecal immunochemical testing (FIT) aims to detect pre-symptomatic colorectal lesions and reduce CRC mortality. The objectives of this study were to determine the FIT sensitivity for diagnosis of CRC, the impact of diagnostic circumstances on treatment and survival, and risk factors for interval cancer (IC). This population-based study evaluated the 2016-2017 CRC screening campaign in Finistère, France. CRCs were classified according to diagnostic circumstances: screen-detected CRC (SD-CRC), CRC with delayed diagnosis, IC after negative FIT (FIT-IC), post-colonoscopy CRC, CRC in non-responders and CRC in the excluded population. This study included 909 CRCs: 248 SD-CRCs (6% of positive FIT) and 60 FIT-ICs (0.07% of negative FIT). The FIT sensitivity for CRC was 80.5% (CI95%: 76.1-84.9) at the threshold of 30 µg hemoglobin/g feces used in France. In multivariate analysis, proximal (OR:6.73) and rectal locations (OR:7.52) were associated with being diagnosed with FIT-IC rather than SD-CRC. The FIT positivity threshold maximizing the sum of sensitivity and specificity was found to be 17 µg/g, with 14 additional CRCs diagnosed compared to the current threshold. Our study confirms the good sensitivity of FIT. A decrease of the FIT detection threshold could optimize sensitivity.

Sections du résumé

BACKGROUND
Colorectal cancer (CRC) screening using fecal immunochemical testing (FIT) aims to detect pre-symptomatic colorectal lesions and reduce CRC mortality.
AIMS
The objectives of this study were to determine the FIT sensitivity for diagnosis of CRC, the impact of diagnostic circumstances on treatment and survival, and risk factors for interval cancer (IC).
METHODS
This population-based study evaluated the 2016-2017 CRC screening campaign in Finistère, France. CRCs were classified according to diagnostic circumstances: screen-detected CRC (SD-CRC), CRC with delayed diagnosis, IC after negative FIT (FIT-IC), post-colonoscopy CRC, CRC in non-responders and CRC in the excluded population.
RESULTS
This study included 909 CRCs: 248 SD-CRCs (6% of positive FIT) and 60 FIT-ICs (0.07% of negative FIT). The FIT sensitivity for CRC was 80.5% (CI95%: 76.1-84.9) at the threshold of 30 µg hemoglobin/g feces used in France. In multivariate analysis, proximal (OR:6.73) and rectal locations (OR:7.52) were associated with being diagnosed with FIT-IC rather than SD-CRC. The FIT positivity threshold maximizing the sum of sensitivity and specificity was found to be 17 µg/g, with 14 additional CRCs diagnosed compared to the current threshold.
CONCLUSIONS
Our study confirms the good sensitivity of FIT. A decrease of the FIT detection threshold could optimize sensitivity.

Identifiants

pubmed: 36764389
pii: S2210-7401(23)00018-9
doi: 10.1016/j.clinre.2023.102093
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

102093

Informations de copyright

Copyright © 2023 Elsevier Masson SAS. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no conflict of interest related to this work.

Auteurs

Mikaël Canévet (M)

Gastroenterology Department, Brest University Hospital, 29200 Brest, France. Electronic address: mikael.canevet@chu-brest.fr.

Manon Pruvost-Couvreur (M)

Digestive tumor registry of Finistère, Brest University Hospital, 29200 Brest, France; EA 7479 SPURBO, Brest University Hospital, Brest, France. Electronic address: couvreur_manon@yahoo.fr.

Marie Morvan (M)

Digestive tumor registry of Finistère, Brest University Hospital, 29200 Brest, France; EA 7479 SPURBO, Brest University Hospital, Brest, France.

Bogdan Badic (B)

Digestive surgery department, Brest University Hospital, 29200 Brest, France. Electronic address: bogdan.badic@chu-brest.fr.

Josiane Brousse-Potocki (J)

CRCDC BRETAGNE, 35000 Rennes, France. Electronic address: Crcdc.bretagne@orange.fr.

Tiphaine Kermarrec (T)

Digestive tumor registry of Finistère, Brest University Hospital, 29200 Brest, France; EA 7479 SPURBO, Brest University Hospital, Brest, France. Electronic address: tiphaine.kermarrec@laposte.net.

Servane Bouzeloc (S)

Digestive tumor registry of Finistère, Brest University Hospital, 29200 Brest, France; EA 7479 SPURBO, Brest University Hospital, Brest, France. Electronic address: servane.bouzeloc@chu-brest.fr.

Jean-Baptiste Nousbaum (JB)

Gastroenterology Department, Brest University Hospital, 29200 Brest, France; Digestive tumor registry of Finistère, Brest University Hospital, 29200 Brest, France; EA 7479 SPURBO, Brest University Hospital, Brest, France. Electronic address: jean-baptiste.nousbaum@chu-brest.fr.

Michel Robaszkiewicz (M)

Gastroenterology Department, Brest University Hospital, 29200 Brest, France; Digestive tumor registry of Finistère, Brest University Hospital, 29200 Brest, France; EA 7479 SPURBO, Brest University Hospital, Brest, France. Electronic address: michel.robaszkiewicz@wanadoo.fr.

Noémi Reboux (N)

Gastroenterology Department, Brest University Hospital, 29200 Brest, France.

Lucille Quénéhervé (L)

Gastroenterology Department, Brest University Hospital, 29200 Brest, France. Electronic address: lucille.queneherve@chu-brest.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH